🇺🇸 FDA

Company profile · Sponsor

Shionogi

Shionogi B.V.

E1EEB33 · EMA pharma EU
Pipeline
6
Drugs
0
Patents
0

Quick answer

Shionogi (E1EEB33) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E1EEB33
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (6)

Search pipeline →

  1. S-217622

    Shionogi

    SARS-CoV-2 Infection

    phase 3 small molecule completed

    1 trial

  2. S-268019-b

    Shionogi

    SARS-CoV-2

    phase 3 small molecule completed

    1 trial

  3. A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of S-337395 in symptomatic nonhospitalized adults with respiratory syncytial virus who are at high risk of progression to severe disease

    Shionogi

    Respiratory Syncytial Virus

    phase 2 other active

    1 trial

  4. Cefiderocol

    Shionogi

    Gram-negative Bacterial Infections

    phase 2 small molecule completed

    1 trial

  5. S-337395

    Shionogi

    Respiratory Syncytial Virus Infections

    phase 2 small molecule active

    1 trial

  6. S-606001 matching placebo, S-606001

    Shionogi

    Late-onset Pompe disease.

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is Shionogi?

Shionogi (E1EEB33) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Shionogi sponsor?

We track 6 ClinicalTrials.gov-linked programs for Shionogi, including S-217622 and 5 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Shionogi company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.